Short Interest Worth Mentioning: How Analysts Feel About Bioshares Biotechnology Clinical (NASDAQ:BBC) After Decrease in Sellers?

November 25, 2016 - By Hazel Jackson   ·   0 Comments

Short Interest Worth Mentioning: How Analysts Feel About Bioshares Biotechnology Clinical (NASDAQ:BBC) After Decrease in Sellers?

The stock of Bioshares Biotechnology Clinical (NASDAQ:BBC) registered a decrease of 10.21% in short interest. BBC’s total short interest was 113,500 shares in November as published by FINRA. Its down 10.21% from 126,400 shares, reported previously. With 6,100 shares average volume, it will take short sellers 19 days to cover their BBC’s short positions. BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) has declined 0.14% since April 22, 2016 and is downtrending. It has underperformed by 5.55% the S&P500.

More notable recent BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) news were published by: Etftrends.com which released: “Reasons to bet on new Breed Biotech ETFs” on April 17, 2015, also Nasdaq.com with their article: “The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P …” published on February 02, 2016, Etftrends.com published: “Silver Lining for Biotechnology ETFs After Pfizer Calls off Allergan Deal” on April 06, 2016. More interesting news about BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) were released by: Seekingalpha.com and their article: “Bioshares New Equal Weight ETFs Offer Diversification And Growth” published on December 22, 2014 as well as Etftrends.com‘s news article titled: “Clinton Delivers Poison Pill To Biotech ETFs” with publication date: September 21, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>